Neuroendocrine Tumors Treatment Pipeline Shows Strong Momentum as 70+ Pharma Companies in the Race | DelveInsight

DelveInsight's, "Neuroendocrine tumors Pipeline Insight 2026" report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Neuroendocrine tumors pipeline landscape. It covers the Neuroendocrine Tumors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Neuroendocrine Tumors pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Neuroendocrine Tumors Pipeline. Dive into DelveInsight's comprehensive report today! @ [https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Neuroendocrine Tumors Pipeline Report

* On February 12, 2026- University of Michigan Rogel Cancer Center initiated a Phase II Trial of Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer. Eligible patients will be treated with the combination of lenvatinib and pembrolizumab. A cycle equals 21 days and therapy will continue until radiographic progression, intolerable toxicity, or patient/physician wishes to discontinue protocol therapy. A maximum of 35 cycles may be administered. On Day 1, when both pembrolizumab and lenvatinib are administered, patients should take the lenvatinib per their normal routine.
* On February 12, 2026- Advanced Accelerator Applications conducted a study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to
* On February 03, 2026- Novartis Pharmaceuticals announced a study was to evaluate the diagnostic performance of [68Ga]Ga-DOTA-TATE Positron Emission Tomography (PET)/Computerized Tomography (CT) imaging compared with conventional imaging (CIM) as standard of truth in patients with neuroendocrine neoplasms (NENs) and healthy volunteers (HVs).
* On February 02, 2026- Jonsson Comprehensive Cancer Center conducted a study is being done to learn more about the drug tarlatamab in people with your condition. The purpose of this study is to see the efficacy (how well something works) of study treatment (tarlatamab) and whether it causes any side effects. Tarlatamab is being developed as an anti-cancer drug for tumors and is FDA-approved for extensive-stage small cell lung cancer. Tarlatamab is investigational for the purpose of this study.
* DelveInsight's Neuroendocrine Tumors pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Neuroendocrine Tumors treatment.
* The leading Neuroendocrine Tumors Companies such as Camurus, Vyriad, Inc., TYK Medicines, Orano Med, Advanced Accelerator Applications, Sinotau Pharmaceutical Group, ITM Solucin GmbH, Molecular Targeting Technologies, Inc., Biotheus Inc., Aadi Bioscience, Inc., TaiRx, Inc. and others.
* Promising Neuroendocrine Tumors Pipeline Therapies such as lanreotide acetate, Lanreotide (Autogel formulation) and Temozolomide, AlphaMedix, Octreotide LAR, and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Neuroendocrine Tumors Treatment Drugs [https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Neuroendocrine Tumors Emerging Drugs Profile

* CAM2029: Camurus

CAM2029 is a long-acting subcutaneous depot of octreotide under development for the treatment of three rare diseases: acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NET) and polycystic liver disease (PLD). Studies completed to date demonstrate that CAM2029 has the potential to provide significantly higher octreotide bioavailability and octreotide exposure with the potential for improved treatment efficacy, compared to current market leading products. CAM2029 is designed to enable easy self-administration, including the option of a pre-filled pen device. Currently, the drug is in the Phase III stage of its development for the treatment of gastroentero pancreatic neuroendocrine tumors.

* AlphaMedix: Orano Med

AlphaMedix is a somatostatin receptor targeting peptide radiolabeled with 212Pb. Somatostatin receptors are overexpressed in most neuroendocrine tumors, a heterogeneous group of rare neoplasms that originate from neuroendocrine cells. These neoplasms occur mostly in the gastrointestinal tract and pancreas, but can also occur in other tissues including thymus, lung, and other uncommon sites such as ovaries, heart, and prostate. After the promising results of the Phase I clinical trial launched early 2018, a Phase II was initiated late 2021 to assess the efficacy of Alphamedix in the treatment of neuroendocrine tumors. The study is currently recruiting patients in the US. Currently the drug is in Phase II stage of its clinical development.

* Voyager-V1: Vyriad, Inc.

VSV-IFN-NIS (Voyager V1; VV1) is derived from VSV, a bullet-shaped, negative-sense RNA virus with low human seroprevalence; it is engineered to replicate selectively in and kill human cancer cells. VV1 encodes hIFN to increase antitumoral immune response and tumor specificity, plus the thyroidal sodium iodide symporter NIS to allow imaging of virus. VV1 is synergistic with different anti-PD-(L)1 antibodies in several tumor models. Currently the drug is in Phase I/II stage of its development.

The Neuroendocrine Tumors Pipeline Report Provides Insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Neuroendocrine Tumors with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuroendocrine Tumors Treatment.
* Neuroendocrine Tumors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Neuroendocrine Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neuroendocrine Tumors market

Access DelveInsight's detailed report now! @ New Neuroendocrine Tumors Drugs [https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Neuroendocrine Tumors Companies

Camurus, Vyriad, Inc., TYK Medicines, Orano Med, Advanced Accelerator Applications, Sinotau Pharmaceutical Group, ITM Solucin GmbH, Molecular Targeting Technologies, Inc., Biotheus Inc., Aadi Bioscience, Inc., TaiRx, Inc. and others.

Neuroendocrine tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intravenous
* Subcutaneous
* Oral
* Intramuscular

Neuroendocrine Tumors Products have been categorized under various Molecule types such as

* Monoclonal antibody
* Small molecule
* Peptide

Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Neuroendocrine Tumors Market Drivers and Barriers [https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Neuroendocrine Tumors Pipeline Report

* Coverage- Global
* Neuroendocrine Tumors Companies- Camurus, Vyriad, Inc., TYK Medicines, Orano Med, Advanced Accelerator Applications, Sinotau Pharmaceutical Group, ITM Solucin GmbH, Molecular Targeting Technologies, Inc., Biotheus Inc., Aadi Bioscience, Inc., TaiRx, Inc. and others.
* Neuroendocrine Tumors Pipeline Therapies- lanreotide acetate, Lanreotide (Autogel formulation) and Temozolomide, AlphaMedix, Octreotide LAR , and others.
* Neuroendocrine Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Neuroendocrine Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight's in-depth pipeline report today! @ Neuroendocrine Tumors Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Neuroendocrine Tumors: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Neuroendocrine Tumors- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* RYZ101: RayzeBio, Inc.
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Ramucirumab: Eli Lilly and Company
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* ADCT-701: ADC Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Neuroendocrine Tumors Key Companies
* Neuroendocrine Tumors Key Products
* Neuroendocrine Tumors- Unmet Needs
* Neuroendocrine Tumors- Market Drivers and Barriers
* Neuroendocrine Tumors- Future Perspectives and Conclusion
* Neuroendocrine Tumors Analyst Views
* Neuroendocrine Tumors Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=neuroendocrine-tumors-treatment-pipeline-shows-strong-momentum-as-70-pharma-companies-in-the-race-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/neuroendocrine-tumors-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.